Paul Mampilly has been making money on Wall Street for over 25 years, ever since 1991. In 2008-2009, he accomplished an incredible investing feat. He entered the investment competition for the Templeton Foundation, named after the famous investor John Templeton who made large amount of money by investing in Japanese companies when their most prestious product was the transistor radio. Mampilly started with $50 million in capital, and turned it into $88 million. That would be amazing in any time period. But Mampilly did it during the Great Recession, but without shorting any investments. In those two years almost every class of financial asset went down, but he found the tiny few that went up instead.
Mampilly stays in touch with technological developments, and that includes the development of precision medicine. For many decades, doctors have prescribed the same medicines for all diseases to all patients. That is often effective for antibiotics fighting the same infectious bacteria. However, other diseases are not so clear-cut. For instance, more recent research has revealed to science that cancer is not one disease that manifests in many different organs. It is at least 200 different diseases. They act in similar ways, all characterized by uncontrolled growth, but they have different genomic profiles. That is, they are caused by different genetic mutations in combination with different environmental factors.
Many drugs that work on one type of cancer do not work on others, even cancers that manifest in the same body organ. And many cancers react in separate ways to different medications. A tyrosine protein kinase inhibitor that works well on one kind of cancer may not work on one that has a different genetic profile.
The first time people mapped the human genome, it was an expensive, massive project that required teams of researchers, millions of dollars and many years. Now it’s becoming routine and inexpensive. When you’re sick, your doctor will examine your genetics, and prescribe treatment based on it. Your genome is uniquely yours. And soon, it will determine which illnesses you are most vulnerable, and which medicine you require.
In an article he wrote after visiting the American Society of Clinical Oncology meeting and seeing the most advanced work being done to fight cancer, he predicted that in fifteen years cancer will be a chronic disease we’ll live with, not the killer we fear today. And cancer is just one example of how medicine and pharmacuetical companies will learn how to treat all patients as individuals.
To know more click: here.